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Pre-B Cell Receptor Signaling Mediates Selective
Response to IL-7 at the Pro-B to Pre-B Cell
Transition via an ERK/MAP Kinase-Dependent Pathway
tiation (Corcoran et al., 1996; Cumano et al., 1990; Wei
et al., 2000), in addition to its survival and proliferative
roles. The most well-characterized signaling conse-
quences of IL-7R dimerization are the activation of PI3K
and JAK/STAT proteins (Hofmeister et al., 1999). Addi-
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University of Toronto tional proteins are beginning to emerge as important
members of the IL-7R signaling cascade, including theOntario, Canada
kinase Pyk2 (Benbernou et al., 2000), which may link IL-7
binding to the Ras pathway (Della Rocca et al., 1997).
The Ras/MEK/ERK pathway is believed to play an impor-Summary
tant role in signals downstream of the pBCR, based on
the ability of a constitutively active Ras transgene toB lymphocyte development is regulated at multiple
checkpoints, mediated by signals originating both in- phenotypically rescue B cell development to the pre-B
cell stage (Shaw et al., 1999a, 1999b). In light of theside and outside the cell. Two signaling pathways known
to be essential in this process are interleukin-7 (IL-7) evidence highlighting the importance of both pBCR- and
IL-7R-mediated signaling in B cell development, it isand the pre-B cell receptor (pBCR). We have shown
previously that these signaling pathways intersect remarkable that a specific mechanism describing their
role in this process has yet to be defined.functionally. Specifically, response to low concentra-
tions of IL-7 requires pBCR expression. In this report, In a previous report, we presented evidence that cells
able to express a functional pBCR exhibit a loweredwe identify the ERK/MAP kinase pathway as a key
regulatory component of this response. We propose threshold for proliferation in response to IL-7 (Marshall et
al., 1998). We proposed that the interaction of the pBCRa molecular mechanism for the selective expansion of
pBCR precursors and for the culling of inappropri- and IL-7R pathways results in the selection of pBCR cells
based on their proliferative advantage over pBCR cellsately rearranged pro-B cells.
in limiting concentrations of IL-7. More recently, another
group has demonstrated that inducible expression ofIntroduction
the pBCR permits proliferation in low concentrations of
IL-7 (Hess et al., 2001). Here, we demonstrate that theGeneration of the B lymphocyte lineage involves the
development of early noncommitted hematopoeitic ability to proliferate in low IL-7 concentrations requires
not only pBCR expression but also a signal downstreamstem cells to mature, Ig-producing B cells. This pathway
requires multiple selection checkpoints to ensure appro- of the pBCR. We show that artificially providing a pBCR
signal by crosslinking a key component of the pBCR,priate progression through the developmental stages.
Among the most important of these selection events are Ig, can restore the ability of pBCR-deficient cells to
proliferate in low concentrations of IL-7. Additionally, wethe production of the B cell antigen receptor (BCR) and
its precursor, the pre-B cell receptor (pBCR) (Meffre demonstrate that the ERK/MAPK pathway is required
downstream of the pBCR in order to mediate this effect.et al., 2000). Surface expression of the pBCR complex
requires productive rearrangement of the immunoglobu- Furthermore, studies with a panel of IL-7-dependent
lines reveal a positive correlation between the expres-lin heavy chain (HC) and its subsequent pairing with the
surrogate light chain (SLC: 5, VpreB) and the signaling sion of the pBCR and constitutive activation of the ERK
family MAP kinases. These results reveal a molecularchains Ig and Ig (Tsubata and Reth, 1990; Venkitara-
man et al., 1991). In the absence of a signal derived from mechanism for selection at this vital checkpoint in B cell
development.an intact pBCR, the cell fails to progress and undergoes
apoptotic elimination (Kurosaki, 2000; Osmond et al.,
1994). The mechanism responsible for this critical selec- Results
tion step has not yet been defined, despite its essential
role in the generation of the B cell lineage. Other path- Expression of the pBCR Correlates with the Ability
ways have been shown to participate in checkpoints to Proliferate in Low Concentrations of IL-7
during B cell development. Interleukin-7 (IL-7), a 25 kDa in Both Fetal and Adult B Cell Precursors
cytokine produced by stromal cells, was identified as a We have proposed a model for selection of pBCR bone
proliferation factor for the B cell lineage (Namen et al., marrow (BM) cells based on their ability to respond to
1988) and has since been shown to promote survival as low levels of IL-7 (Marshall et al., 1998). In this study we
well. Disruption of the IL-7 signaling pathway prevents designate “high” IL-7 concentrations to be in the range
the appearance of the pBCR-expressing population in of 1–25 ng/ml, and “low” IL-7 concentrations as 10–100
the bone marrow (Hofmeister et al., 1999). However, pg/ml. MT mice harbor a deletion in the transmem-
expression of the bcl-2 gene in IL-7-deficient cells fails brane domain of the Ig heavy chain (HC) gene, resulting
to restore B cell development (Maraskovsky et al., 1998), in their inability to express surface pBCR complexes
consistent with other evidence that IL-7 effects differen- (Kitamura et al., 1991). Pro-B cells isolated from MT
adult BM exhibit a significant reduction in proliferation
in response to low concentrations of IL-7 relative to1 Correspondence: heatherf@oci.utoronto.ca
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WT-derived pro-B cells (Figure 1A; Marshall et al., 1998).
As shown in Figure 1B, precursors isolated from the
fetal liver environment exhibit a similar response profile,
demonstrating that pBCR expression is required for pro-
liferation in response to low concentrations of IL-7 in
both developmental compartments. We generated IL-7-
dependent cell lines by growing B220 BM cells at lim-
iting dilutions in the presence of IL-7. Both pBCR and
pBCR lines can be isolated from cultures derived from
WT BM. As shown in Figure 1C, populations that express
surface pBCR complexes exhibit a 5- to 10-fold increase
in proliferation relative to pBCR lines in 20–80 pg/ml
IL-7. These studies reveal that pBCR surface expression
correlates with proliferation in reduced concentrations
of IL-7 and provide us with an experimental model sys-
tem in which biochemical studies may be performed.
Stimulation of the pBCR Signaling Chain on pBCR
Cells Rescues Proliferation in Low Concentrations
of IL-7
The results presented above suggest that a signal re-
sulting from pBCR expression, perhaps derived from
the pBCR itself, is required to allow proliferation in low
concentrations of IL-7. The HC protein possesses a
short cytoplasmic tail, and all signaling by pBCR and
BCR complexes is believed to be mediated by the ITAM-
containing Ig and Ig chains. A monoclonal antibody,
HM79, which recognizes the extracellular portion of Ig
(Koyama et al., 1997) has been shown to mimic pBCR-
derived signals in vivo in a RAG-deficient mouse model
(Nagata et al., 1997). We tested the hypothesis that this
pBCR-like signal would be sufficient to allow prolifera-
tion of RAG2/-derived pBCR populations in low con-
centrations of IL-7 and found, as shown in Figure 2A,
that this was the case. Similar results were found utilizing
pro-B cells from a MT background (Figure 2B). These
results support our proposal that proliferation in low
amounts of IL-7 requires not only pBCR expression but
also signals downstream of the pBCR.
Increased ERK/MAPK Activation in the Presence
of Combined pBCR and IL-7R Signaling
To examine signals downstream of the pBCR, a panel
of IL-7-dependent, pBCR cell lines was used to monitor
biochemical changes mediated by the IL-7R in the pres-
ence or absence of pBCR stimulation. Given that anti-
Ig crosslinking can induce ERK1 activation in RAG-
deficient BM cells (Nagata et al., 1997), we tested
whether this MAP kinase pathway is involved in pBCR
cells responding to IL-7. ERK1,2 MAPK activation was
measured by performing Western blots with phosphory-
lation-state specific antibodies to the ERK kinases and
also against a target protein of the ERK kinases, p90Rsk
(Blenis, 1993). Comparing the time course of ERK and
closed triangles; B62.1, closed squares) or do not express the pBCR
Figure 1. Expression of pBCR Correlates with the Ability to Prolifer- (H2-4, open circles; H2-6, open triangles; H3-2, open squares). Pro-
ate in Low Concentrations of IL-7 liferation was assayed by [3H] thymidine incorporation after 4 days
Proliferation assays were performed in a titration of IL-7 using: (A) in culture. Data is presented as the mean of triplicate wells; error
pro-B cells sorted from BM of MT (open triangles) or C57BL/6 bars represent SD. Plots are representative of at least four (A), two
(open circles) mice; (B) B cell precursors isolated from d15 FL of (B), or five (C) independent experiments. Significance was deter-
MT (open triangles) or C57BL/6 (open circles) mice; (C) IL-7-depen- mined by an unpaired two-tailed student’s T test (*** p  0.0001,
dent cell lines that express the pBCR (B23, closed circles; H1-1, ** p  0.001, * p  0.005).
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Figure 2. Proliferation of pBCR pro-B Cells in Low IL-7 Concentra-
tions Can Be Rescued with anti-Ig Stimulation
Sorted BM pro-B cells from (A) RAG2/ and RAG2/ and (B) MT
and C57BL/6 mice were plated in triplicate with the indicated con-
centrations of IL-7. Ig was crosslinked by the addition of the indi-
cated concentration of the mAb, HM79, at the initiation of culture.
Isotype control was added at 10 g/ml. Proliferation was assayed
Figure 3. Activation of ERK/MAPK Is Greater Following Combined
as in Figure 1. Significance was determined by an unpaired two-
anti-pBCR and IL-7R Stimulation
tailed student’s T test (*** p  0.0001, ** p  0.001, * p  0.02).
(A) The pBCR IL-7-dependent line, B62c, was starved of IL-7 and
stimulated with anti- F(ab)2, IL-7, or both for the indicated times.
One sample was treated with 0.4 M sorbitol as a control for p38/
Rsk phosphorylation following each independent stimu- JNK stimulation used in (B). Western blotting was performed for
lus reveals that pBCR-derived activation is immediate phospho-ERK1,2 or phospho-p90Rsk. The blots were stripped and
reprobed with a pan-ERK1,2 or a pan-p90Rsk antibody. This blotand transient (Figure 3A, lanes 1, 3, 6, 9, and 12), whereas
is representative of at least four experiments and was consistent inIL-7-induced phosphorylation is relatively delayed but
two other pBCR cell lines.prolonged (Figure 3A, lanes 1, 2, 5, 8, and 11). As shown
(B) B62c cells were stimulated as in (A) for the indicated times or
in Figure 3A, when both stimuli are combined, more with 0.4 M sorbitol for 30 min. Western blotting was performed
phosphorylated ERK1,2 is detected relative to the level with a phospho-JNK antibody and then reblotted for phospho-p38,
of ERK activation observed in the presence of indepen- without stripping.
(C) IL-7-responsive precursors were isolated from RAG2/HCtgdent receptor stimulation. In addition, the same result
BM. Cells were stimulated as in (A) and assayed for ERK phosphory-is obtained when a signal through the pBCR is initiated
lation. This result is representative of two independent experiments.by crosslinking Ig according to the method described
(D) B62c cells were starved and incubated with biotinylated -Ig
by Nagata et al. (1997) (Figure 3D). These results suggest (HM79) or isotype control for 5 min on ice. Ig was crosslinked by
that activation of the ERK/MAPK pathway can occur the addition of streptavidin for an additional 5 min at 37	C in the
downstream of both the pBCR and the IL-7R concur- presence or absence of 20 ng/ml IL-7. Western blotting was performed
as in (A). This result is representative of three independent experiments.rently. Figure 3B demonstrates that other MAPK path-
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ways, p38 and JNK/SAPK, do not appear to be activated
in this system.
Increased Activation of ERK Observed in Ex Vivo
Isolated pBCR Cells following Combined IL-7R
and pBCR Stimulation
The results described above were obtained using cell
lines that have been selected for continuous in vitro
growth in IL-7. To examine the levels of ERK activation
following pBCR signals in an ex vivo population, IL-7-
dependent cells were grown from RAG2/HCtg mice
(Young et al., 1994). Nonadherent BM cells were grown
in IL-7 for 7 days. The phenotype of the resultant popula-
tion was that of transitional pro-/pre-B cells (99% B220;
95% CD24, CD25; 70% BP1; 50% CD2; 40%
5-SLC, CD43; 30% CD22; not detected: CD40, 
LC,
CD3, MAC1, GR1; data not shown). Using this culture
method, sufficient cell numbers were generated to test
whether primary pro-B cells were similar to IL-7-depen-
dent cell lines in their ability to activate ERK. As shown
in Figure 3C, additional ERK activation was observed in
the presence of both IL-7 and pBCR stimuli relative to
the level of ERK activity detected following stimulation of
either receptor alone. This confirms that pBCR-derived
signals are able to activate ERK when stimulated in the
presence of IL-7. The activation of ERK observed in the
presence of both stimuli could result from an additive
effect of stimulating two independent pools of ERK1,2.
ERK Activation Is Required for Proliferation but Not
Differentiation of pBCR Cells in Low Concentrations
of IL-7
The results obtained by Western blot analysis show that
combined IL-7R and pBCR signals lead to higher levels
of ERK/MAPK phosphorylation than is found with either
stimulus alone. This raises the possibility that the prolif-
eration of pBCR cells observed in low concentrations
of IL-7 is ERK dependent. According to this hypothesis,
the limited amount of ERK activated by low concentra-
tions of IL-7 may be supplemented by ERK activation
downstream of the pBCR. In pBCR cells, no additional
ERK would be phosphorylated, resulting in the failure
of cells to proliferate. This model predicts that prolifera-
tion in low concentrations of IL-7 is dependent on reach-
ing a threshold of ERK phosphorylation. To test this
prediction, an inhibitor of MEK1 kinase (Alessi et al.,
1995) was used to specifically inhibit the activation of
ERK/MAPK (Figure 4A) by pBCR and pBCR cells in Figure 4. Inhibition of MEK Kinase Prohibits Proliferation of IL-7-
a titration of IL-7. The proliferation of pBCRpopulations Dependent pBCR Cells in Low Concentrations of IL-7
(Figure 4B) but not a pBCR line (Figure 4C) is inhibited (A) B62c cells were starved and incubated in the presence of DMSO
or a MEK inhibitor, PD98059, for 1 hr prior to stimulation. Westernin a dose-dependent manner in the presence of the
blotting for phosphorylated MEK1,2 and ERK1,2 reveals a loss of MEKMEK1 inhibitor, PD98059. In contrast, treatment with
activity and ERK activation following treatment with this inhibitor.LY294002, a PI3K inhibitor (Vlahos et al., 1994), pre-
(B and C) Proliferation in a titration of IL-7 was assayed in the
vented proliferation in both pBCR and pBCR cells at presence of PD98059, at 10 M (open triangles) and 20 M (open
all concentrations of IL-7, consistent with the known squares) or in the presence of solvent alone (DMSO, open circles).
requirement for PI3K in IL-7-induced mitogenic re- Populations tested include (B) B23, a pBCR IL-7-dependent line,
and (C) 23, an IL-7-dependent, pBCR line. The proliferation ofsponses (Corcoran et al., 1996) (Figures 4B and 4C).
23 (dashed line) is included in (B) as a reference for proliferationThis result was extended by examining IL-7-induced
expected in the absence of pBCR-derived signals. Treatment ofproliferation of freshly sorted pro-B cells from RAG2/
both populations with a PI3K inhibitor, LY294002 (closed circles),
and RAG2/ mice in the presence of another inhibitor inhibits proliferation at all IL-7 concentrations. Data is presented as
of MEK1/2, UO126 (Favata et al., 1998). As observed in the mean of triplicate wells, and error bars represent SD. Results
the IL-7-dependent lines, MEK inhibition leads to a loss are representative of at least three independent experiments and
are consistent in multiple IL-7-dependent cell lines.of proliferation of RAG pro-B cells (Figure 5A). This
pBCR/ERK Signals Regulate IL-7 Responsiveness
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Figure 5. ERK1,2 Activation Is Required for the Proliferation but Not Differentiation of Sorted pro-B Cells in Low Concentrations of IL-7
(A) Proliferation of sorted pro-B cells from RAG2/ mice was assayed in a titration of IL-7 in the presence of another MEK inhibitor, U0126,
at 5 M (open triangles) or 20 M (open squares), the PI3K inhibitor (LY294002, closed circles), or solvent alone (open circles). The proliferation
of untreated RAG2/ cells is included for reference (dashed line).
(B) RAG2/ and RAG2/ pro-B cells were cultured in high or low concentrations of IL-7 in the presence of a MEK inhibitor (PD98059), p38
inhibitor (SB203580), PI3K inhibitor (LY294002), or DMSO control. Proliferation was assayed by [3H] thymidine incorporation on day 4 of culture.
Error bars represent SD of triplicate wells. Significance was determined by an unpaired two-tailed student’s T test (*p  0.005).
(C) FACS analysis of HC expression was performed in sorted RAG2/ pro-B cells grown for 5 days in the presence of the indicated
concentrations of IL-7 and inhibitor, or DMSO control. The absolute number of total and HC cells recovered in each condition is indicated.
Results shown are representative of two (A and C) or four (B) independent experiments.
effect is consistent when PD98059 is used to inhibit the a reduced absolute number of cells is recovered from
PD98059-treated cultures grown in low amounts of IL-7RAG2 precursors in low concentrations of IL-7 (Figure
5B). Only RAG2/ cells exhibit dose-dependent inhibi- (2.7 0.2-fold reduction; Figure 5C and data not shown),
a less dramatic reduction in HC cell number is ob-tion of proliferation when cultured with the MEK inhibi-
tor. In contrast, neither RAG2/ nor RAG2/ popula- served (1.8  0.05-fold reduction; Figure 5C and data
not shown) in conditions that elicit very low levels oftions are inhibited by treatment with a p38/MAP kinase
inhibitor (Cuenda et al., 1995), suggesting a specific proliferation (Figures 5A and 5B). Together, these results
suggest that pBCR-dependent activation of ERK is re-involvement of the ERK/MAP kinase pathway (Figure
5B). Finally, the sorted pro-B cells exhibit sensitivity to quired for proliferation but not differentiation in low con-
centrations of IL-7.PI3K inhibition at all concentrations of IL-7 (Figure 5B).
FACS analysis of the sorted pro-B cells was per-
formed to examine the possibility that treatment with the Enforced Survival Is Insufficient to Permit pBCR
Populations to Proliferate in Low ConcentrationsMEK inhibitors prevented their proliferation by blocking
maturation to the pre-B cell stage. As shown in Figure of IL-7
The result that ERK activity is required for proliferation5C, inhibition of ERK activation by PD98059 treatment
does not prevent the development of HC cells in low in low concentrations of IL-7 does not distinguish be-
tween a direct mitogenic effect of ERK downstream tar-concentrations of IL-7. In fact, there is an increase in
the percentage of mature cells in the MEK1-inhibited gets and the possibility that induced survival signals
permit an alternative proliferative stimulus to act (Na-population relative to that observed following treatment
with solvent alone or with the p38 inhibitor. Indeed, while gaoka et al., 2000; Shaw et al., 1999b). To address the
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Figure 6. Enforced Survival of pBCR Cells Is Insufficient to Allow Their Proliferation in Low Concentrations of IL-7
(A and B) Pro-B cells were sorted from RAG2/ and RAG2/ mice with or without a bcl-2 transgene, plated at 5000 cells/well in a titration
of IL-7, and cultured for 4 days. Replicate triplicate wells were assayed for total cell recovery (A) or proliferation (B). Results shown are
representative of two independent experiments, and error bars represent SD. Significance was determined by an unpaired two-tailed student’s
T test (** p  0.001, * p  0.002).
(C and D) H3-3, a pBCR IL-7-dependent cell line, was grown in a titration of IL-7 in the presence of a caspase inhibitor (z-VAD-FMK, [C] left
panel, [D] triangles) or a control cathepsin B inhibitor (z-FA-FMK, [C] right panel, [D] squares) for 4 days. Immediately prior to the addition of
[3H] thymidine to assay proliferation (D), micrographs were taken of wells grown in 100 pg/ml IL-7 (indicated with an arrow in [D]) to assess
cell survival. Representative pictures are shown in (C). The size bar indicates 50 M. Results shown are representative of two independent
experiments and are consistent in multiple cell lines.
question of whether survival is sufficient to allow prolif- Higher Constitutive Levels of ERK Activation in pBCR
IL-7-Dependent Lines Relative to pBCR Lineseration of pBCR cells in low IL-7, we sorted pro-B cells
from RAG2/bcl-2 transgenic mice and compared their The model described above suggests that pBCR ex-
pression leads to proliferation in reduced concentra-ability to proliferate with that of RAG2/- and RAG2/-
derived populations. As shown in Figure 6A, while ex- tions of IL-7 by activating ERK. We examined a panel
of unstimulated IL-7-dependent cell lines to determinepression of the bcl-2 transgene does permit the survival
of RAG2/ cells as the concentration of IL-7 is lowered whether there was a correlation between pBCR expres-
sion and constitutive levels of ERK/MAPK activation.in culture (Figure 6A), it is insufficient to allow prolifera-
tion in low concentrations of IL-7 (Figure 6B). We recog- As shown in Figure 7A, elevated levels of constitutively
phosphorylated ERK1,2 are observed in pBCR linesnize that overexpression of bcl-2 may prevent prolifera-
tion by altering cell cycle state (Figure 6B; Mazel et al., (lanes 1, 2, and 3) relative to pBCR lines (lanes 4, 5,
and 6). Furthermore, a pBCR cell line selected for its1996; Vairo et al., 1996). Therefore, we also treated a
pBCR IL-7-dependent cell line with a wide-spectrum ability to grow in the absence of IL-7 exhibits the highest
background levels of ERK phosphorylation (Figure 7A,caspase inhibitor (z-VAD-FMK, Thornberry and Lazeb-
nik, 1998) or a control inhibitor (Z-FA-FMK, Schotte et al., lane 1: IND). Also, while this line retains its ability to
proliferate in response to IL-7 stimulation (Figure 7B),1999). While inhibition of caspase activity does promote
survival in low concentrations of IL-7 (Figure 6C), this short-term treatment with IL-7 does not increase ERK1,2
phosphorylation (Figure 7A, lane 1 versus 7) in contrastmethod of enforced survival is not sufficient to allow
pBCR cells to proliferate (Figure 6D). to the IL-7-dependent lines (Figure 7A, lanes 2–6 versus
pBCR/ERK Signals Regulate IL-7 Responsiveness
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Figure 7. Constitutive Levels of ERK Phos-
phorylation Correlate with pBCR Expression
and the Ability to Proliferate in Low IL-7
(A) A panel of cell lines that express (IND,
B23, B62.1) or do not express (B62, H24, 23)
the pBCR were starved of IL-7 and left unstimu-
lated (lanes 1–6) or stimulated with IL-7.
Lysates were assayed for phosphorylated
ERK1,2 as in Figure 3.
(B) The IND line (lanes 1 and 7) was assayed
for proliferation in response to an IL-7 titration
in the presence of 5 M PD98059 (open cir-
cles), 20 M PD98059 (open triangles), 500
nM SB203580 (p38 inhibitor, closed triangles),
or solvent alone (DMSO, open squares). The
proliferation of uninhibited pBCR (B23,
closed circles) and pBCR (23, closed
squares) cells are included as reference IL-7-
dependent lines.
lanes 8–12). Finally, the IND line is no longer able to dependent cell lines correlates with increased constitu-
tive ERK phosphorylation. Together, these observationsproliferate in the absence of IL-7 when treated with the
suggest a simple molecular mechanism that mediatesMEK1 inhibitor but is unaffected by the presence of the
the pro-B to pre-B transition checkpoint. We show thatp38 inhibitor, SB203580 (Figure 7B and data not shown).
the levels of phosphorylated ERK produced in responseThese results are consistent with our model that pBCR
to IL-7 stimulation is increased in cells receiving a pBCRexpression leads to ERK activation, which promotes
signal. We suggest that this additional source of acti-selection by permitting proliferation in concentrations
vated kinase, unavailable to pBCR cells, creates suffi-of IL-7 that are insufficient to support the expansion of
cient downstream effectors to allow the proliferation ofpBCR cells.
the pBCR population in low concentrations of IL-7.
We have shown here that a signal downstream of
Discussion the pBCR signaling chain is sufficient to alter the IL-7
responsiveness of a developmentally arrested popula-
The generation of a functionally rearranged HC that tion (see Figure 2). Cellular changes following the mem-
can associate with the component chains of the pBCR brane insertion of the pBCR include allelic exclusion at
is an absolute requirement for B cell development. To the HC locus, a limited burst of cell division, a variety
date, the mechanism underlying this requirement is of cell surface marker changes, and eventual initiation
largely unexplained (Meffre et al., 2000). In this report, of recombination at the light chain locus (Meffre et al.,
we show that (1) pBCR expression by adult and fetal 2000). The components of the pBCR complex have been
pre-B cells and IL-7-dependent cell lines correlates with manipulated in order to dissect which portion signals
the ability to proliferate in low concentrations of IL-7; for which changes within the cell. In most model sys-
(2) a signal downstream of the pBCR signaling chain is tems, the ITAM sequences of Ig or Ig appear to be
sufficient to mediate this effect; (3) concurrent stimula- required to mediate pBCR-derived effects (Meffre et al.,
tion of the pBCR and the IL-7R specifically activates the 2000). However, a transgenic model using a HC mu-
ERK/MAP kinase pathway; (4) ERK activation is required tated such that it could not associate with Ig/ was
for pBCR-mediated proliferation but not differentiation used to show that development was blocked, while al-
lelic exclusion remained intact (Cronin et al., 1998). Simi-in minimal IL-7; and (5) expression of the pBCR in IL-7-
Immunity
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larly, transgenic LMP2A models indicate that expression events leads to the proliferation of pBCR cells in low
concentrations of IL-7, it appears that the requirementof an ITAM is sufficient to turn off recombination at the
HC locus (Caldwell et al., 1998; Merchant et al., 2000). for ERK activation in the lowering of the IL-7 response
threshold is downstream of pBCR expression.In addition, the treatment of MT pro-B cells with an
anti-Ig monoclonal antibody can signal allelic exclu- As discussed above, activated Ras transgenes can
rescue development in pBCR-deficient animals. Whilesion in the absence of the pBCR (Maki et al., 2000).
These results demonstrate that activation of an ITAM this effect may be due to multiple arms of the MAP
kinase pathway, we believe that our observations arecan mediate allelic exclusion prior to formation of the
pBCR complex and may indicate that Ig signals have specific to the ERK1,2 family members. No phosphoryla-
tion of the JNK/SAPK and p38 proteins is observed bya role in differentiation prior to those downstream of the
pBCR. This raises an interesting point regarding our own Western blot (Figure 3B), and an inhibitor of p38 activity
is unable to alter the proliferation of any IL-7-dependentuse of the anti-Ig antibody to mimic a pBCR signal,
in that a “pro-BCR” signal induced by HM79 may be line at any IL-7 concentration tested (Figures 5B and
7B; data not shown). No data concerning the effects ofsufficient to mediate a decrease in the IL-7 response
threshold. However, Iritani et al. (1999) have demon- ERK1 deficiency on the B cell lineage are available, and
the alterations observed in the T lineage are minimal,strated that pBCR-like signals mediated by a constitu-
tively activate cRaf-1 transgene are distinct from those likely due to some amount of functional redundancy
between the two proteins (Pages et al., 1999). The typesthat lead to allelic exclusion, suggesting that the prolifer-
ation we induce with anti-Ig treatment may not be due of stimuli that lead to either proliferation or differentia-
tion via ERK activation in nerve cells have been studiedto the early pro-BCR signaling capacity of the Ig ITAM.
In either case, we have shown that Ig signals can medi- extensively (Fukunaga and Miyamoto, 1998). Intrigu-
ingly, the time course of ERK activation may alter theate a decrease in the IL-7 response threshold and that
a functional HC is required in the absence of artificially outcome of the signal by determining whether or not
activated ERK translocates to the nucleus (Marshall,stimulated Ig.
We show that activation of the ERK/MAP kinase path- 1995). Preliminary studies suggest that phosphorylated
ERK does translocate to the nucleus following all ofway is required to permit proliferation of pBCR cells
in low concentrations of IL-7. Other groups have shown stimuli used in this study (data not shown), but further
experiments are in progress to address whether a pBCRthat ERK can be activated downstream of the pBCR,
BCR, and the IL-7R (Healy et al., 1997; Nagata et al., signal can alter the subcellular localization of activated
ERK.1997; Sutherland et al., 1996; Zeng et al., 1994). We have
demonstrated that pBCR expression correlates with an Considerable speculation and effort have surrounded
the attempt to identify the natural ligand for the pBCR.increase in constitutively phosphorylated ERK (Figure
7A) and that in the absence of ERK activation, pBCR In the absence of an identified ligand, it has been postu-
lated that signaling through the pBCR is initiated simplylines exhibit proliferation equivalent to pBCR lines (Fig-
ures 4B and 5A). However, we cannot conclude from by surface expression of the receptor (Kurosaki, 2000).
According to our model, this would suggest that pBCRthese results that phosphorylated ERK leads directly
to proliferation. We considered that pBCR expression cells should express constitutively higher levels of acti-
vated ERK. This is, in fact, what is observed in our panelcould transmit a survival signal, allowing cells to persist
and proliferate in cultures containing low amounts of of cell lines (Figure 7A). The parallel observation has
been made in the T cell lineage, where ERK phosphoryla-IL-7. This is supported by the observations that constitu-
tive activation of the Ras pathway mediates survival in tion was induced following pTCR expression, in the ab-
sence of any exogenous stimulation (Michie et al., 1999).developing B cells (Nagaoka et al., 2000; Shaw et al.,
1999b) and that transgenic expression of the LMP2A Indeed, in our in vitro experiments, the mere presence
of surface-expressed pBCR is sufficient for proliferationITAM confers survival signals to pBCR cells, even in
the absence of phenotypic differentiation (Caldwell et in low concentrations of IL-7 (Marshall et al., 1998) (Fig-
ure 1). In addition, this proliferation is unaltered by theal., 2000). Consistent with the observation that bcl-2
transgene expression does not rescue development in addition of antibodies that crosslink the pBCR (Stoddart
et al., 2001) (Figure 2; data not shown). However, whileRAG2/ mice (Young et al., 1997), we demonstrated
that simply keeping pBCR cells alive is not sufficient no known ligand has been added to these cultures, it
is possible that a ligand for the pBCR may exist on theto permit proliferation in the presence of low IL-7 con-
centrations (Figure 6). These results do not preclude a cultured cells themselves.
The results presented here and discussed above sup-role for survival signals mediated by either the pBCR
and/or the IL-7R, but it is clear that more than the survival port our model for selection of pBCR cells, in which a
signal downstream of the pBCR induces ERK/MAP ki-of pBCR cells accounts for their ability to proliferate in
low concentrations of IL-7. Alternatively, pBCR-derived nase phosphorylation to a level that is sufficient to allow
proliferation in low concentrations of IL-7. The absencesignals may induce maturational changes that lead to
ERK-dependent proliferation. We have observed that of pBCR-derived ERK activation in pBCR cells would
prevent them from proliferating at concentrations thatERK inhibition does not prevent phenotypic maturation
in our IL-7 cultures (Figure 5C). In fact, considering the support pBCR cell growth. This sets up a situation in
which pBCR cells will be selectively expanded in anabsolute number of HC cells recovered from wells
that exhibit very little thymidine incorporation (Figure 5), environment where IL-7 is limiting. Apparently, these
conditions still allow Ig cells to arise in the nonex-the frequency of maturation may be enhanced in low
concentrations of IL-7 in the absence of ERK activity. panding population, offering the possibility of recovery
should an appropriate receptor be expressed. AccurateWhile we cannot rule out that a series of maturation
pBCR/ERK Signals Regulate IL-7 Responsiveness
529
ion laser regulated to emit 125 mW power at 488 nm. CyCLOPSin vivo measurement of IL-7 concentrations is difficult
Summit software builds b574 and b619 were used for acquisitionand may not reflect the amount of IL-7 that is functionally
and analysis. Typically, 0.5%–1.0% of total BM was recovered fromactive and available to the B cell precursors. Extracellu-
C57BL/6 and RAG2/ mice, and 3%–5% of MT and RAG2/ BM
lar matrix proteins can bind and inactivate cytokines was recovered from the sort. Sorted populations were routinely
(Amara et al., 1999; Clarke et al., 1995), while cell surface 97% pure. Enrichment of pro-B cells from d15 FL was performed
by panning as described (Ray et al., 1998). Typically, 2–3  107 cellsheparan sulfate on B cells and stromal cells can specifi-
were recovered per d15 C57BL/6 or MT FL, 0.8%–1% of whichcally bind active IL-7 (Borghesi et al., 1999). Another
were B220.report has shown that a stromal-derived protein can
dimerize IL-7 monomers and that exposure to these
Cell Culture Conditionscomplexes is required to induce IL-7-monomer respon-
Cells were grown in OptiMEM (Gibco) supplemented with 10% FCS,siveness at the pro-B cell stage (Lai et al., 1998; Mc-
50 M 2-ME, 2.4 g/L NaHCO3, 100 g/ml penicillin, 100 g/ml strep-Kenna et al., 1998). Finally, the ability of individual stro- tomycin, and the indicated factors. For proliferation assays, cells
mal cells to produce IL-7 varies substantially (Gimble et were plated in triplicate at 5000 cells/well in 96-well flat-bottom
plates in the presence of the indicated concentration of recombinantal., 1989; Kincade et al., 1989; Stephan et al., 1998).
mouse IL-7 (R&D Systems, Minneapolis, MN) or medium alone. Anti-Together, these observations suggest that the availabil-
Ig (HM79, type 2 hamster IgG, Pharmingen) was added at theity of IL-7 in the mouse may be quite dynamic. Several
indicated concentrations at the initiation of culture. Inhibitorsgroups have assayed the in vivo effects of IL-7 by artifi-
(PD98059, U0126, LY294002 [New England Biolabs]; SB203580,
cially increasing the concentration by way of enforced z-VAD-FMK, z-FA-FMK [Calbiochem]) were solubilized in DMSO and
transgenic expression, systemic injection, or continuous added at the initiation of culture. Proliferation of cells was measured
on day 4 by addition of 0.5 Ci [3H] thymidine (Mandel, Guelph,subcutaneous infusion (Mertsching et al., 1996; Valen-
Ontario) 6 hr prior to the end of culture. Lysed cells were harvestedzona et al., 1998, 1996). All of these methods have re-
onto microplate filters, and radioactivity was measured in a scintilla-vealed excessive proliferation of both pro- and pre-B cell
tion counter (Topcount System, Canberra Packard, Meriden, CT).populations, suggesting that the in vivo concentrations
For FACS analysis of differentiation shown in Figure 5C, sorted pro-
were limiting under unmanipulated conditions. A report B cells were plated at 2.5  104 cells/well in a 24-well plate, with
has been published describing the effects of IL-7 trans- the indicated concentrations of IL-7 and inhibitors. FACS analysis
was performed as described (Marshall et al., 1998) with a HC-gene expression on B cell development in mice with
specific monoclonal antibody, 33.60-FITC. Cell counts shown inspecific defects in this process (Ceredig et al., 1999).
Figure 6A were performed in duplicate on triplicate wells that hadThey demonstrate that increased in vivo IL-7 concentra-
been set up in parallel with wells assayed for proliferation. IL-7-tions do not restore development in pBCR-deficient
dependent lines were maintained in OptiMEM with 5% FCS and
backgrounds but can allow populations of pBCR cells 5–10 ng/ml murine IL-7 from the supernatant of the stably trans-
to exist in the periphery. This is in agreement with our fected J558 line (Dr. A. Cumano, Pasteur Institute, Paris). IL-7-
responsive pBCR populations were isolated from RAG2/HCtgmodel that increased responsiveness to IL-7 plays a
BM by selection of nonadherent cells grown in OptiMEM 10% FCSselective role in normal B cell development, ensuring
and 10 ng/ml murine IL-7. IL-7-dependent cell lines were isolated bythat only pBCR cells are able to continue to mature
limiting dilution of B220-panned BM cells (Ray et al., 1998) grownand emigrate to the periphery. It should be noted that
in the absence of stromal cells in OptiMEM  10% FCS  5 ng/
while IL-7 can induce proliferation and other effects in ml murine IL-7 for 6 to 8 weeks. The IL-7-independent cell line, IND,
human B cell precursors, there is no apparent require- was isolated by limiting dilution of the pBCR line, B23, grown in
20 pg/ml IL-7 for 6 weeks.ment for an IL-7 signal during human B cell development
(LeBien, 2000). We would propose that an alternative
factor is responsible for selective expansion of pBCR Cell Stimulation and Western Blotting
Prior to stimulation, cells were washed in OptiMEM  0.5% FCS toprecursors in the human bone marrow environment. In
remove IL-7 and starved for 1.5–2 hr in a 37	C humidified incubatorsummary, our data provide a rational basis for under-
at 5  106 cells/ml. Cells were resuspended at 107 cells/ml at 37	Cstanding the molecular processes that regulate this vital
and stimulated by the addition of 10–20 g/ml F(ab)2 goat anti-checkpoint in B cell development. mouse HC (Jackson Immunoresearch), 10–25 ng/ml murine IL-7,
or both, for the times indicated. Positive control samples for JNK/
Experimental Procedures p38 activation were stimulated with 0.4 M sorbitol (Sigma) for 30
min. Cells were lysed at 5  107 cells/ml in 1% NP40, 150 mM NaCl,
Mice 20 mM Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM sodium fluoride, 1
MT mice (Kitamura et al., 1991) were obtained through Dr. L. Shultz mM sodium orthovanadate, 5 mM sodium pyrophosphate, 1 mM
(The Jackson Laboratory, Bar Harbor, ME). RAG2/ (Shinkai et al., PMSF, and 5 g/ml aprotinin and leupeptin (Boehringer Mannheim)
1992) and RAG2/ HC186 transgenic (Young et al., 1994) mice were on ice for 20 min. The detergent insoluble fraction was removed by
provided by Dr. F. Alt (The Children’s Hospital, Boston, MA). RAG2/ centrifugation. Protein samples (equivalent of 6  105–1.2  106
mice were generated by crossing RAG2/ mice with C57BL/6 mice cells) were mixed with 4 NuPAGE sample buffer (Invitrogen) and
(Jackson). bcl-2 transgenic mice (Jackson) were crossed with 0.7 M 2-ME, resolved on a gradient NuPAGE gel, and transferred
RAG2/ mice to obtain double mutants. All mice were bred and to a PVDF membrane in 20 mM Tris/150 mM glycine/20% methanol.
maintained at the Ontario Cancer Institute animal facility (Toronto, Detection of phosphorylated ERK1,2, p90Rsk, MEK1,2, JNK/SAPK,
Canada) and were used between 6 and 10 weeks of age. Timed and p38 was performed according to the manufacturer’s instruc-
pregnancies of C57BL/6 and MT mice were established by mating tions (NEB). For loading controls, membranes were stripped in 6.25
mice overnight and observing vaginal plugs in the morning, day 0. mM TRIS (pH 6.8), 2% SDS, and 100 mM 2-ME (50	C, 25 min),
washed in TBST, and reprobed as above. Stimulation by Ig cross-
linking was adapted from the method of Nagata et al. (1997). CellsCell Purification
Cell suspensions of BM and day 15 FL were prepared as described were starved as above and incubated at 2  107 cells/ml on ice with
30 g/ml HM79-biotin or isotype control for 5 min. Samples were(Marshall et al., 1998; Ray et al., 1998). B cell progenitors (CD19,
CD43, HC) were enriched from BM as described (Marshall et stimulated for a further 5 min at 37	C with the addition of 20 g/ml
streptavidin with or without 20 ng/ml IL-7. The reaction was stoppedal., 1998) with a “MoFlo” (Cytomation, Inc.) high speed cell sorter
equipped with a dual-beam, water-cooled Innova Enterprise II Argon by the addition of cold wash buffer (150 mM NaCl, 20 mM Tris-
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HCl [pH 7.4], 1 mM EDTA, 10 mM sodium fluoride, 1 mM sodium D.A., Feeser, W.S., Van Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F.,
et al. (1998). Identification of a novel inhibitor of mitogen-activatedorthovanadate, and 5 mM sodium pyrophosphate) followed by centi-
fugation. Cell lysis and sample preparation were performed as protein kinase kinase. J. Biol. Chem. 273, 18623–18632.
above. Fukunaga, K., and Miyamoto, E. (1998). Role of MAP kinase in neu-
rons. Mol. Neurobiol. 16, 79–95.
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